Advances in therapeutic strategies for the treatment of pruritus

Carolyn Stull, Michael J. Lavery, Gil Yosipovitch

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Introduction: Chronic pruritus is a common symptom that arises from both dermatologic and non-dermatologic conditions including chronic kidney disease, cholestasis, lymphoma and neuropathy. Over the past decade, research has elucidated many of the receptors, neuropeptides and cytokines involved in itch sensation and transmission. In addition, the first biomarker for cholestatic itch has been discovered. These findings have led to the development of a host of novel antipruritic medications, both on the market and in the pipeline. Areas covered: A summary of new and emerging treatments for pruritus, as well as possible targets for future therapeutic development is provided. Expert opinion: At present, there is no universally effective treatment available for all types of chronic pruritus. A combination of topical and systemic therapies addressing peripheral mediators, and a top-down approach targeting the brain and spinal cord, seems preferable to a single agent approach. Neural hypersensitization plays a significant role in many forms of chronic pruritus and may be downregulated by new treatments. In addition, specific neuropeptides are now targeted by novel antipruritic therapies. Furthermore, targeted biologic agents are anticipated to play a significant role in treating pruritus of inflammatory origin.

Original languageEnglish (US)
Pages (from-to)671-687
Number of pages17
JournalExpert Opinion on Pharmacotherapy
Volume17
Issue number5
DOIs
StatePublished - Mar 23 2016
Externally publishedYes

Fingerprint

Pruritus
Antipruritics
Therapeutics
Neuropeptide Receptors
Cytokine Receptors
Cholestasis
Expert Testimony
Biological Factors
Neuropeptides
Chronic Renal Insufficiency
Lymphoma
Spinal Cord
Down-Regulation
Biomarkers
Brain
Research

Keywords

  • antipruritics
  • Atopic dermatitis
  • autotaxin
  • biologics
  • chronic pruritus
  • IL-31
  • nerve growth factor
  • neural hypersensitization
  • neuropeptides
  • nonhistaminergic itch
  • psoriasis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Advances in therapeutic strategies for the treatment of pruritus. / Stull, Carolyn; Lavery, Michael J.; Yosipovitch, Gil.

In: Expert Opinion on Pharmacotherapy, Vol. 17, No. 5, 23.03.2016, p. 671-687.

Research output: Contribution to journalReview article

Stull, Carolyn ; Lavery, Michael J. ; Yosipovitch, Gil. / Advances in therapeutic strategies for the treatment of pruritus. In: Expert Opinion on Pharmacotherapy. 2016 ; Vol. 17, No. 5. pp. 671-687.
@article{1dbb38cf24104ed28fd576af18c511df,
title = "Advances in therapeutic strategies for the treatment of pruritus",
abstract = "Introduction: Chronic pruritus is a common symptom that arises from both dermatologic and non-dermatologic conditions including chronic kidney disease, cholestasis, lymphoma and neuropathy. Over the past decade, research has elucidated many of the receptors, neuropeptides and cytokines involved in itch sensation and transmission. In addition, the first biomarker for cholestatic itch has been discovered. These findings have led to the development of a host of novel antipruritic medications, both on the market and in the pipeline. Areas covered: A summary of new and emerging treatments for pruritus, as well as possible targets for future therapeutic development is provided. Expert opinion: At present, there is no universally effective treatment available for all types of chronic pruritus. A combination of topical and systemic therapies addressing peripheral mediators, and a top-down approach targeting the brain and spinal cord, seems preferable to a single agent approach. Neural hypersensitization plays a significant role in many forms of chronic pruritus and may be downregulated by new treatments. In addition, specific neuropeptides are now targeted by novel antipruritic therapies. Furthermore, targeted biologic agents are anticipated to play a significant role in treating pruritus of inflammatory origin.",
keywords = "antipruritics, Atopic dermatitis, autotaxin, biologics, chronic pruritus, IL-31, nerve growth factor, neural hypersensitization, neuropeptides, nonhistaminergic itch, psoriasis",
author = "Carolyn Stull and Lavery, {Michael J.} and Gil Yosipovitch",
year = "2016",
month = "3",
day = "23",
doi = "10.1517/14656566.2016.1127355",
language = "English (US)",
volume = "17",
pages = "671--687",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Advances in therapeutic strategies for the treatment of pruritus

AU - Stull, Carolyn

AU - Lavery, Michael J.

AU - Yosipovitch, Gil

PY - 2016/3/23

Y1 - 2016/3/23

N2 - Introduction: Chronic pruritus is a common symptom that arises from both dermatologic and non-dermatologic conditions including chronic kidney disease, cholestasis, lymphoma and neuropathy. Over the past decade, research has elucidated many of the receptors, neuropeptides and cytokines involved in itch sensation and transmission. In addition, the first biomarker for cholestatic itch has been discovered. These findings have led to the development of a host of novel antipruritic medications, both on the market and in the pipeline. Areas covered: A summary of new and emerging treatments for pruritus, as well as possible targets for future therapeutic development is provided. Expert opinion: At present, there is no universally effective treatment available for all types of chronic pruritus. A combination of topical and systemic therapies addressing peripheral mediators, and a top-down approach targeting the brain and spinal cord, seems preferable to a single agent approach. Neural hypersensitization plays a significant role in many forms of chronic pruritus and may be downregulated by new treatments. In addition, specific neuropeptides are now targeted by novel antipruritic therapies. Furthermore, targeted biologic agents are anticipated to play a significant role in treating pruritus of inflammatory origin.

AB - Introduction: Chronic pruritus is a common symptom that arises from both dermatologic and non-dermatologic conditions including chronic kidney disease, cholestasis, lymphoma and neuropathy. Over the past decade, research has elucidated many of the receptors, neuropeptides and cytokines involved in itch sensation and transmission. In addition, the first biomarker for cholestatic itch has been discovered. These findings have led to the development of a host of novel antipruritic medications, both on the market and in the pipeline. Areas covered: A summary of new and emerging treatments for pruritus, as well as possible targets for future therapeutic development is provided. Expert opinion: At present, there is no universally effective treatment available for all types of chronic pruritus. A combination of topical and systemic therapies addressing peripheral mediators, and a top-down approach targeting the brain and spinal cord, seems preferable to a single agent approach. Neural hypersensitization plays a significant role in many forms of chronic pruritus and may be downregulated by new treatments. In addition, specific neuropeptides are now targeted by novel antipruritic therapies. Furthermore, targeted biologic agents are anticipated to play a significant role in treating pruritus of inflammatory origin.

KW - antipruritics

KW - Atopic dermatitis

KW - autotaxin

KW - biologics

KW - chronic pruritus

KW - IL-31

KW - nerve growth factor

KW - neural hypersensitization

KW - neuropeptides

KW - nonhistaminergic itch

KW - psoriasis

UR - http://www.scopus.com/inward/record.url?scp=84951272702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951272702&partnerID=8YFLogxK

U2 - 10.1517/14656566.2016.1127355

DO - 10.1517/14656566.2016.1127355

M3 - Review article

C2 - 26630350

AN - SCOPUS:84951272702

VL - 17

SP - 671

EP - 687

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -